Morgan Stanley Gh Research PLC Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Gh Research PLC stock. As of the latest transaction made, Morgan Stanley holds 281,002 shares of GHRS stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

281,002

Previous 277,251 1.35%

Holding current value

$3.93 Million

Previous $3.06 Million 12.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$8.66 - $13.79 $32,483 - $51,726	3,751 Added 1.35%	281,002 $3.43 Million
Q1 2025 May 15, 2025	BUY	$7.91 - $17.99 $93,203 - $211,976	11,783 Added 4.44%	277,251 $3.06 Million
Q4 2024 Feb 14, 2025	BUY	$6.3 - $10.95 $43,142 - $74,985	6,848 Added 2.65%	265,468 $1.86 Million
Q3 2024 May 14, 2025	SELL	$6.69 - $12.49 $222,944 - $416,229	-33,325 Reduced 11.41%	258,620 $1.73 Million
Q3 2024 Nov 14, 2024	SELL	$6.69 - $12.49 $222,944 - $416,229	-33,325 Reduced 11.41%	258,620 $1.73 Million
Q2 2024 May 14, 2025	BUY	$10.5 - $14.81 $278,008 - $392,124	26,477 Added 9.97%	291,945 $3.4 Million
Q2 2024 Oct 17, 2024	BUY	$10.5 - $14.81 $111,625 - $157,445	10,631 Added 3.78%	291,945 $3.4 Million
Q2 2024 Aug 14, 2024	BUY	$10.5 - $14.81 $111,625 - $157,445	10,631 Added 3.78%	291,945 $3.4 Million
Q1 2024 Oct 17, 2024	SELL	$5.34 - $11.09 $56,769 - $117,897	-10,631 Reduced 3.64%	281,314 $3 Million
Q1 2024 Aug 16, 2024	SELL	$5.34 - $11.09 $218,491 - $453,758	-40,916 Reduced 12.7%	281,314 $3 Million
Q1 2024 May 15, 2024	SELL	$5.34 - $11.09 $218,491 - $453,758	-40,916 Reduced 12.7%	281,314 $3 Million
Q4 2023 Aug 16, 2024	BUY	$5.26 - $11.04 $159,299 - $334,346	30,285 Added 10.37%	322,230 $1.87 Million
Q4 2023 Feb 13, 2024	BUY	$5.26 - $11.04 $79,010 - $165,831	15,021 Added 4.89%	322,230 $1.87 Million
Q3 2023 Nov 15, 2023	SELL	$9.8 - $14.15 $847,984 - $1.22 Million	-86,529 Reduced 21.98%	307,209 $3.09 Million
Q2 2023 Aug 14, 2023	BUY	$7.88 - $12.74 $14,838 - $23,989	1,883 Added 0.48%	393,738 $4.67 Million
Q1 2023 May 15, 2023	SELL	$6.02 - $10.92 $796,205 - $1.44 Million	-132,260 Reduced 25.23%	391,855 $3.13 Million
Q4 2022 Feb 14, 2023	BUY	$9.2 - $13.5 $319,966 - $469,516	34,779 Added 7.11%	524,115 $5.09 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $16.15 $108,777 - $173,079	10,717 Added 2.24%	489,336 $5.69 Million
Q2 2022 Oct 27, 2022	BUY	$8.99 - $19.87 $513,967 - $1.14 Million	57,171 Added 13.57%	478,619 $4.78 Million
Q2 2022 Aug 15, 2022	BUY	$8.99 - $19.87 $513,967 - $1.14 Million	57,171 Added 13.57%	478,619 $4.78 Million
Q1 2022 Oct 27, 2022	SELL	$15.48 - $23.98 $885,007 - $1.37 Million	-57,171 Reduced 11.94%	421,448 $7.71 Million
Q1 2022 May 13, 2022	SELL	$15.48 - $23.98 $356,241 - $551,851	-23,013 Reduced 5.18%	421,448 $7.71 Million
Q4 2021 Feb 14, 2022	BUY	$14.1 - $27.9 $284,834 - $563,607	20,201 Added 4.76%	444,461 $10.4 Million
Q3 2021 Nov 15, 2021	BUY	$16.51 - $23.68 $7 Million - $10 Million	424,260 New	424,260 $9.36 Million

Others Institutions Holding GHRS

# of Institutions

Shares Held

38.5M

Call Options Held

Put Options Held

2.6K

View Full List

About GH Research PLC

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $728M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

More about GHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account